Utilization of antiepileptic drugs in Israel

被引：15
作者：
Berman, Erez [1 ]
Marom, Eli [1 ]
Ekstein, Dana [2 ]
Blatt, Ilan [3 ,4 ]
Eyal, Sara [5 ]
机构：
[1] Israel Minist Hlth, Dept Pharmacol, Jerusalem, Israel
[2] Hadassah Hebrew Univ Med Ctr, Dept Neurol, Agnes Ginges Ctr Neurogenet, Jerusalem, Israel
[3] Sheba Med Ctr, Dept Neurol, Tel Hashomer, Israel
[4] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[5] Hebrew Univ Jerusalem, Inst Drug Res, Sch Pharm, Fac Med, Jerusalem, Israel
来源：
EPILEPSY & BEHAVIOR | 2016年 / 61卷
关键词：
Antiepileptic drugs; Drug utilization; Drug preparations; NATIONWIDE POPULATION; OPIOID ANALGESICS; EPILEPSY; TRENDS; CONSUMPTION; PATTERNS; EXPOSURE; CHILDREN; AGE;
D O I：
10.1016/j.yebeh.2016.05.004
中图分类号：
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号：
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要：
Purpose: The aim of the study was to identify trends in utilization of antiepileptic drugs (AEDs) over time in a nation-wide population in Israel. Methods: Data on AED utilization (for all indications) for the period 2010-2014 were obtained from pharmaceutical companies that distribute AEDs in Israel. Prevalence of AED utilization was reported as defined daily doses (DDD)/1000 inhabitants/day. Results: The utilization of most AEDs included in our analysis remained stable over the study period. The greatest increases in utilization of drugs established in Israel were observed for lamotrigine (33%), oxcarbazepine (31%), and primidone (18%). Decreases in use were recorded for carbamazepine (18%) and phenobarbital (15%). Use of older AEDs appeared to be relatively high, compared with the use of newer AEDs. Conclusions: During the study period of 2010-2014, conventional AED5 remained a main treatment choice in Israel, in certain cases in contrast to current recommendations and guidelines, for reasons yet to be revealed in further research. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码：82 / 85
页数：4
相关论文
共 24 条
[1]  
American Epilepsy Society, 2007, AES POS SUBST DIFF F
[2]  
[Anonymous], 5 WHO COLL CTR DRUG
[3]  
Benet O, 2012, ISRAELI LEAGUE EPILE
[4]   Key factors in the discovery and development of new antiepileptic drugs [J].
Bialer, Meir ;
White, H. Steve .
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (01) :68-82
[5]   Antiepileptic drug use in seven electronic health record databases in Europe: A methodologic comparison [J].
de Groot, Mark C. H. ;
Schuerch, Markus ;
de Vries, Frank ;
Hesse, Ulrik ;
Oliva, Belen ;
Gil, Miguel ;
Huerta, Consuelo ;
Requena, Gema ;
de Abajo, Francisco ;
Afonso, Ana S. ;
Souverein, Patrick C. ;
Alvarez, Yolanda ;
Slattery, Jim ;
Rottenkolber, Marietta ;
Schmiedl, Sven ;
Van Dijk, Liset ;
Schlienger, Raymond G. ;
Reynolds, Robert ;
Klungel, Olaf H. .
EPILEPSIA, 2014, 55 (05) :666-673
[6]   Concomitant therapy in people with epilepsy: Potential drug-drug interactions and patient awareness [J].
Eyal, Sara ;
Rasaby, Sivan ;
Ekstein, Dana .
EPILEPSY & BEHAVIOR, 2014, 31 :369-376
[7]   Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany-a nationwide population-based study in children and adults [J].
Hamer, Hajo M. ;
Dodel, Richard ;
Strzelczyk, Adam ;
Balzer-Geldsetzer, Monika ;
Reese, Jens-Peter ;
Schoeffski, Oliver ;
Graf, Wolfgang ;
Schwab, Stefan ;
Knake, Susanne ;
Oertel, Wolfgang H. ;
Rosenow, Felix ;
Kostev, Karel .
JOURNAL OF NEUROLOGY, 2012, 259 (11) :2376-2384
[8]   Comparison of antiepileptic drug prescribing in children in three European countries [J].
Hsia, Yingfen ;
Neubert, Antje ;
Sturkenboom, Miriam C. J. M. ;
Murray, Macey L. ;
Verhamme, Katia M. C. ;
Sen, Fatma ;
Giaquinto, Carlo ;
Ceci, Adriana ;
Wong, Ian C. K. .
EPILEPSIA, 2010, 51 (05) :789-796
[9]   Trends in the use of antiepileptic drugs in Taiwan from 2003 to 2007: A Population-Based National Health Insurance study [J].
Hsieh, Liang-Po ;
Huang, Chin-Yin .
EPILEPSY RESEARCH, 2011, 96 (1-2) :81-88
[10]   Use and safety profile of antiepileptic drugs in Italy [J].
Iorio, M. L. ;
Moretti, U. ;
Colcera, S. ;
Magro, L. ;
Meneghelli, I. ;
Motola, D. ;
Rivolta, A. L. ;
Salvo, F. ;
Velo, G. P. .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (04) :409-415
123